Profile data is unavailable for this security.
About the company
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
- Revenue in CAD (TTM)0.00
- Net income in CAD-96.59k
- Incorporated1996
- Employees0.00
- LocationQuest Pharmatech Inc4342 97 StreetEDMONTON T6E 5R9CanadaCAN
- Phone+1 (780) 448-1400
- Fax+1 (780) 448-1400
- Websitehttp://www.questpharmatech.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rakovina Therapeutics Inc | 0.00 | -8.36m | 3.07m | -- | -- | 1.62 | -- | -- | -0.5705 | -0.5705 | 0.00 | 0.0893 | 0.00 | -- | -- | -- | -158.14 | -- | -221.29 | -- | -- | -- | -- | -- | -- | -21.46 | 0.579 | -- | -- | -- | -55.86 | -- | -- | -- |
| XORTX Therapeutics Inc | 0.00 | -2.66m | 3.39m | 3.00 | -- | 0.9389 | -- | -- | -0.6465 | -0.6465 | 0.00 | 0.5179 | 0.00 | -- | -- | -- | -58.35 | -39.11 | -94.63 | -43.59 | -- | -- | -- | -- | -- | -- | 0.0291 | -- | -- | -- | -53.53 | -- | 48.96 | -- |
| StageZero Life Sciences Ltd | -100.00bn | -100.00bn | 4.86m | 40.00 | -- | -- | -- | -- | -- | -- | -- | -0.1232 | -- | -- | -- | -- | -- | -135.76 | -- | -- | -- | -2.74 | -- | -246.92 | 0.0177 | -- | -- | -- | -25.12 | 55.93 | -52.53 | -- | -- | -- |
| Telo Genomics Corp | 0.00 | -2.71m | 5.03m | 8.00 | -- | -- | -- | -- | -0.0289 | -0.0289 | 0.00 | -0.0003 | 0.00 | -- | -- | -- | -517.19 | -98.53 | -51,970.82 | -111.33 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -0.2116 | -- | -- | -- |
| Quest PharmaTech Inc | 0.00 | -96.59k | 5.07m | 0.00 | -- | 0.2198 | -- | -- | -0.0006 | -0.0006 | 0.00 | 0.1365 | 0.00 | -- | -- | -- | -0.398 | 10.66 | -0.4181 | 11.12 | -- | -- | -- | -- | -- | -- | 0.0415 | 0.00 | -- | -- | 40.32 | -- | -- | -- |
| COSCIENS Biopharma Inc | 12.38m | -20.39m | 7.39m | 21.00 | -- | 1.06 | -- | 0.5965 | -6.47 | -6.47 | 3.92 | 2.18 | 0.2678 | 1.96 | 5.18 | -- | -44.08 | -24.51 | -53.74 | -27.91 | 45.14 | 62.83 | -164.63 | -175.84 | 3.03 | -- | 0.2994 | -- | 34.22 | 78.30 | -339.28 | -- | -- | -- |
